Tienilic acid, a uricosuric diuretic, in the treatment of heart failure

Karl Weber, A. P. Fishman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To evaluate the safety and efficacy of tienilic acid (TA), an oral diuretic agent with uricosuric properties, in the management of cardiac failure, two double-blind studies with TA and hydrochlorothiazide (HCT) were undertaken. Twenty-one patients were randomly assigned to tienilic acid (TA) for 6 weeks in Study I while 17 patients received TA for 12 weeks in Study II; ten patients were given HCT in each study. Throughout both study periods there were no statistical differences between TA and HCT with respect to the incidence, frequency or severity of exertional dyspnoea, nocturnal dyspnoea, orthopnoea or fatigue, stability of body weight, and haematocrit, serum electrolytes, urea nitrogen or creatinine. In distinct constrast to HCT, serum uric acid was significantly (P<0.05) lowered with TA on most observation days throughout each study. There were only two major untoward effects noted in patients receiving TA: one patient receiving both diphenylhydantoin and TA experienced slurred speech, confusion, ataxia and dizziness suggesting diphenylhydantoin toxicity; the other patient had a serum sickness type of allergic reaction 14 days after having received TA and quinidine sulphate. It is concluded that TA is a safe and effective diuretic of moderate potency, similar to HCT, which should prove useful in the diuretic management of many patients with heart failure.

Original languageEnglish (US)
Pages (from-to)58-62
Number of pages5
JournalPostgraduate Medical Journal
Volume55
Issue numberSUPPL.3
StatePublished - Dec 1 1979

Fingerprint

Ticrynafen
Treatment Failure
Diuretics
Heart Failure
Hydrochlorothiazide
Phenytoin
Dyspnea
Uricosuric Agents
Serum Sickness
Confusion
Quinidine
Dizziness
Ataxia
Uric Acid
Serum
Hematocrit
Double-Blind Method
Electrolytes
Fatigue
Urea

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Tienilic acid, a uricosuric diuretic, in the treatment of heart failure. / Weber, Karl; Fishman, A. P.

In: Postgraduate Medical Journal, Vol. 55, No. SUPPL.3, 01.12.1979, p. 58-62.

Research output: Contribution to journalArticle

@article{97082dd8fbe746a9883be9281926b61a,
title = "Tienilic acid, a uricosuric diuretic, in the treatment of heart failure",
abstract = "To evaluate the safety and efficacy of tienilic acid (TA), an oral diuretic agent with uricosuric properties, in the management of cardiac failure, two double-blind studies with TA and hydrochlorothiazide (HCT) were undertaken. Twenty-one patients were randomly assigned to tienilic acid (TA) for 6 weeks in Study I while 17 patients received TA for 12 weeks in Study II; ten patients were given HCT in each study. Throughout both study periods there were no statistical differences between TA and HCT with respect to the incidence, frequency or severity of exertional dyspnoea, nocturnal dyspnoea, orthopnoea or fatigue, stability of body weight, and haematocrit, serum electrolytes, urea nitrogen or creatinine. In distinct constrast to HCT, serum uric acid was significantly (P<0.05) lowered with TA on most observation days throughout each study. There were only two major untoward effects noted in patients receiving TA: one patient receiving both diphenylhydantoin and TA experienced slurred speech, confusion, ataxia and dizziness suggesting diphenylhydantoin toxicity; the other patient had a serum sickness type of allergic reaction 14 days after having received TA and quinidine sulphate. It is concluded that TA is a safe and effective diuretic of moderate potency, similar to HCT, which should prove useful in the diuretic management of many patients with heart failure.",
author = "Karl Weber and Fishman, {A. P.}",
year = "1979",
month = "12",
day = "1",
language = "English (US)",
volume = "55",
pages = "58--62",
journal = "Postgraduate Medical Journal",
issn = "0032-5473",
publisher = "BMJ Publishing Group",
number = "SUPPL.3",

}

TY - JOUR

T1 - Tienilic acid, a uricosuric diuretic, in the treatment of heart failure

AU - Weber, Karl

AU - Fishman, A. P.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - To evaluate the safety and efficacy of tienilic acid (TA), an oral diuretic agent with uricosuric properties, in the management of cardiac failure, two double-blind studies with TA and hydrochlorothiazide (HCT) were undertaken. Twenty-one patients were randomly assigned to tienilic acid (TA) for 6 weeks in Study I while 17 patients received TA for 12 weeks in Study II; ten patients were given HCT in each study. Throughout both study periods there were no statistical differences between TA and HCT with respect to the incidence, frequency or severity of exertional dyspnoea, nocturnal dyspnoea, orthopnoea or fatigue, stability of body weight, and haematocrit, serum electrolytes, urea nitrogen or creatinine. In distinct constrast to HCT, serum uric acid was significantly (P<0.05) lowered with TA on most observation days throughout each study. There were only two major untoward effects noted in patients receiving TA: one patient receiving both diphenylhydantoin and TA experienced slurred speech, confusion, ataxia and dizziness suggesting diphenylhydantoin toxicity; the other patient had a serum sickness type of allergic reaction 14 days after having received TA and quinidine sulphate. It is concluded that TA is a safe and effective diuretic of moderate potency, similar to HCT, which should prove useful in the diuretic management of many patients with heart failure.

AB - To evaluate the safety and efficacy of tienilic acid (TA), an oral diuretic agent with uricosuric properties, in the management of cardiac failure, two double-blind studies with TA and hydrochlorothiazide (HCT) were undertaken. Twenty-one patients were randomly assigned to tienilic acid (TA) for 6 weeks in Study I while 17 patients received TA for 12 weeks in Study II; ten patients were given HCT in each study. Throughout both study periods there were no statistical differences between TA and HCT with respect to the incidence, frequency or severity of exertional dyspnoea, nocturnal dyspnoea, orthopnoea or fatigue, stability of body weight, and haematocrit, serum electrolytes, urea nitrogen or creatinine. In distinct constrast to HCT, serum uric acid was significantly (P<0.05) lowered with TA on most observation days throughout each study. There were only two major untoward effects noted in patients receiving TA: one patient receiving both diphenylhydantoin and TA experienced slurred speech, confusion, ataxia and dizziness suggesting diphenylhydantoin toxicity; the other patient had a serum sickness type of allergic reaction 14 days after having received TA and quinidine sulphate. It is concluded that TA is a safe and effective diuretic of moderate potency, similar to HCT, which should prove useful in the diuretic management of many patients with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0018729581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018729581&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 58

EP - 62

JO - Postgraduate Medical Journal

JF - Postgraduate Medical Journal

SN - 0032-5473

IS - SUPPL.3

ER -